English Español
Donate

Clinical Trials

A clinical trial is a research study that tries to find better ways to prevent, screen for, diagnose, or treat a disease like bladder cancer.  They are an essential part of cancer research.  Trials may provide possible treatment alternatives to patients who have not had success with standard and approved therapies.

You can search for a clinical trial below by bladder cancer disease state, state of residence and you can also look for trials nearest to you.

About Clinical Trials

✕To help find trials near you, you need to allow BCAN to access your location
Ok

Featured Trials
Title State Sponsoring Organization
Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC Multi-State Revolution Medicines, Inc.
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Multi-State IDEAYA Biosciences
Study of DF1001 in Patients With Advanced Solid Tumors Multi-State Dragonfly Therapeutics
IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group Kansas University of Kansas Medical Center
Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients Multi-State Theralase Inc.
Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma Multi-State Inhibrx, Inc.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Multi-State National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Multi-State National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Multi-State National Cancer Institute (NCI)
Title State Sponsoring Organization
Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC Multi-State Revolution Medicines, Inc.
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Multi-State IDEAYA Biosciences
Study of DF1001 in Patients With Advanced Solid Tumors Multi-State Dragonfly Therapeutics
IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group Kansas University of Kansas Medical Center
Intravesical Photodynamic Therapy (PDT) in BCG Refractory/Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients Multi-State Theralase Inc.
Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma Multi-State Inhibrx, Inc.
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Multi-State National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Multi-State National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Multi-State National Cancer Institute (NCI)

This Clinical Trials Dashboard is proudly sponsored by the Astellas/Seagen alliance, AstraZeneca, Gilead, LOXO Oncology, Seagen and Tyra Biosciences.

Learn more about the different phases clinical trials here.

Read Our Stories